RESULTS: Based on the Chinese and international guidelines, expert consensus statements, literatures and evidence-based clinical practice experiences, this consensus statement puts forward the clinical implications, application subjects, detection techniques and results interpretations of the triple-biomarker (AFP, AFP-L3%, DCP) based GALAD, GALAD like models for liver cancer.
CONCLUSIONS: The compile of this consensus statement aims to address and push the reasonable application of the triple-biomarker (AFP, AFP-L3%, DCP) detections thus to maximize the clinical benefits and help improving the high risk surveillance, early diagnosis and prognosis of HCC.
结果:根据中国和国际准则,专家共识声明,文献和循证临床实践经验,这一共识声明提出了临床意义,申请科目,三重生物标志物的检测技术和结果解释(AFP,AFP-L3%,DCP)基于GALAD,GALAD像肝癌模型。
结论:本共识声明的汇编旨在解决和推动三重生物标志物(AFP,AFP-L3%,DCP)检测,从而最大限度地提高临床效益,并帮助改善高风险监测,肝癌的早期诊断和预后。